comprehensive -WSS

comprehensive

author：leisure time 2025-10-02 00:41:47 - browse：8

The Food and Drug Administration on Tuesday approved brexanolone, the first drug specifically targeted to treat postpartum depression — the most common complication of childbirth. Yet it’s a condition that often goes untreated because new mothers fear being stigmatized if they report symptoms.

Brexanolone is the first drug developed by and approved from Sage Therapeutics. The Cambridge, Mass.-based biotech company will market the new medicine under the brand name Zulresso.

“This approval is important for postpartum depression patients and it’s important for our company. It’s rare in your career when you can introduce a new medicine that is different from what’s out there,” said Sage CEO Jeff Jonas.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： HHS names first

WSS

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

Congressmen charge Covid hearing ‘could have been an email’

The SUPPORT Act is critical to fighting the opioid crisis

Idaho abortion case may prompt more restrictions in other states

Congressmen charge Covid hearing ‘could have been an email’

Generative AI mines health records to identify patients’ social needs

Wikipedia

comprehensive

focus

Affirmative action in medical school literally saved lives

Covid misinformation case heads to Supreme Court

Medical leaders decry Supreme Court decision on affirmative action

New Medicare drug pricing powers could soon be upended in court

BioMarin wins approval for gene therapy to treat hemophilia A

New Medicare drug pricing powers could soon be upended in court

Cancer drug shortages should be causing more outrage

Vertigo drug brings hope for rare neuron disorder, Niemann

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

A $475,000 price tag for a new cancer drug: crazy or meh?

focus

Health and fitness trackers are measuring the wrong things

Novo Nordisk to expand supply of Wegovy for U.S. patients

New Ultima Genomics DNA sequencer can read genome for $100

The lessons of Aduhelm, an Alzheimer's drug that was not to be

Biotech reporter’s notebook: A sunnier mood at JPM 2024

Readout LOUD podcast: 2023 in review, and a look at biotech in 2024

Wikipedia

focus

hotspot

hotspot